![The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology](https://cdn.amegroups.cn/journals/pbpc/files/journals/1/articles/181/public/181-PB15-4535-R1.png/w300)
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
![IJMS | Free Full-Text | CA 19-9 Pancreatic Tumor Marker Fluorescence Immunosensing Detection via Immobilized Carbon Quantum Dots Conjugated Gold Nanocomposite IJMS | Free Full-Text | CA 19-9 Pancreatic Tumor Marker Fluorescence Immunosensing Detection via Immobilized Carbon Quantum Dots Conjugated Gold Nanocomposite](https://pub.mdpi-res.com/ijms/ijms-19-01162/article_deploy/html/images/ijms-19-01162-sch003.png?1570011465)
IJMS | Free Full-Text | CA 19-9 Pancreatic Tumor Marker Fluorescence Immunosensing Detection via Immobilized Carbon Quantum Dots Conjugated Gold Nanocomposite
![Introduction and overview of CA19-9 CA19-9 is a tumour associated antigen found in the blood serum. CA 19-9 is also known as the Sialylated Lewis-antigen. - ppt download Introduction and overview of CA19-9 CA19-9 is a tumour associated antigen found in the blood serum. CA 19-9 is also known as the Sialylated Lewis-antigen. - ppt download](https://slideplayer.com/10165346/34/images/slide_1.jpg)
Introduction and overview of CA19-9 CA19-9 is a tumour associated antigen found in the blood serum. CA 19-9 is also known as the Sialylated Lewis-antigen. - ppt download
![Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer](http://old.scielo.br/img/revistas/ramb/v56n1/10t01.gif)
Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer
![Usefulness of Carbohydrate Antigen 19-9 Test in Healthy People and Necessity of Medical Follow-up in Individuals with Elevated Carbohydrate Antigen 19-9 Level Usefulness of Carbohydrate Antigen 19-9 Test in Healthy People and Necessity of Medical Follow-up in Individuals with Elevated Carbohydrate Antigen 19-9 Level](https://www.kjfm.or.kr/upload//thumbnails/kjfm-18-0057f1.jpg)
Usefulness of Carbohydrate Antigen 19-9 Test in Healthy People and Necessity of Medical Follow-up in Individuals with Elevated Carbohydrate Antigen 19-9 Level
![CA 19–9 levels are increased in the serum of stage II, III, and IV PDAC... | Download Scientific Diagram CA 19–9 levels are increased in the serum of stage II, III, and IV PDAC... | Download Scientific Diagram](https://www.researchgate.net/publication/272943196/figure/fig6/AS:341559015952392@1458445423794/CA-19-9-levels-are-increased-in-the-serum-of-stage-II-III-and-IV-PDAC-patients-CA-19-9.png)
CA 19–9 levels are increased in the serum of stage II, III, and IV PDAC... | Download Scientific Diagram
![CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2001025641/2003896921/gr1.gif)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
![Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies](http://www.tropicalgastro.com/uploads/Untitlnkged-30.jpg)
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
![Patients with normal‑range CA19‑9 levels represent a distinct subgroup of pancreatic cancer patients Patients with normal‑range CA19‑9 levels represent a distinct subgroup of pancreatic cancer patients](https://www.spandidos-publications.com/article_images/ol/13/2/ol-13-02-0881-g00.jpg)